| Gary B. Pitt Dpm Inc | |
|
59-229 Alapio Rd, Haleiwa, HI 96712-9604 | |
| (808) 638-7589 | |
| Not Available |
| Full Name | Gary B. Pitt Dpm Inc |
|---|---|
| Type | Facility |
| Speciality | Podiatrist - Foot & Ankle Surgery |
| Location | 59-229 Alapio Rd, Haleiwa, Hawaii |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1306032180 | NPI | - | NPPES |
| 021483-3 | Other | HI | HMSA |
| 08802101 | Medicaid | HI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213ES0103X | Podiatrist - Foot & Ankle Surgery | PO136 (Hawaii) | Primary |
| Provider Name | Gary B Pitt |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1992805923 PECOS PAC ID: 4385535764 Enrollment ID: I20050117000224 |
News Archive
An international team of researchers led by Imperial College London has identified six new genetic variants associated with type-2 diabetes in South Asians. The findings, published in Nature Genetics, give scientists new leads in the search for diagnostic markers and drug targets to prevent and treat this major disease.
Finite resources, social inequality, climate change, terrorism - the world is facing major challenges. The UN's "Sustainable Development Goals" constitute a social contract for the world community.
Scientists at the University of California, San Diego School of Medicine report that regeneration of central nervous system axons can be achieved in rats even when treatment delayed is more than a year after the original spinal cord injury.
The Food and Drug Administration (FDA) has approved the approval of Qutenza (capsaicin) 8% patch, a medicated skin patch that relieves the pain of post-herpetic neuralgia (PHN), a serious complication that can occur after a bout with shingles.
Celldex Therapeutics, Inc. today reported financial results for the third quarter ended September 30, 2010. Celldex reported a net loss of $9.1 million, or $0.28 per share, for the third quarter of 2010 compared to a net loss of $7.2 million, or $0.45 per share, for the third quarter of 2009. For the nine months ended September 30, 2010, Celldex reported a net loss of $25.2 million, or $0.79 per share, compared to a net loss of $23.6 million, or $1.49 per share, for the nine months ended September 30, 2009.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Gary B. Pitt Dpm Inc 59-229 Alapio Rd, Haleiwa, HI 96712-9604 Ph: (808) 638-7589 | Gary B. Pitt Dpm Inc 59-229 Alapio Rd, Haleiwa, HI 96712-9604 Ph: (808) 638-7589 |
News Archive
An international team of researchers led by Imperial College London has identified six new genetic variants associated with type-2 diabetes in South Asians. The findings, published in Nature Genetics, give scientists new leads in the search for diagnostic markers and drug targets to prevent and treat this major disease.
Finite resources, social inequality, climate change, terrorism - the world is facing major challenges. The UN's "Sustainable Development Goals" constitute a social contract for the world community.
Scientists at the University of California, San Diego School of Medicine report that regeneration of central nervous system axons can be achieved in rats even when treatment delayed is more than a year after the original spinal cord injury.
The Food and Drug Administration (FDA) has approved the approval of Qutenza (capsaicin) 8% patch, a medicated skin patch that relieves the pain of post-herpetic neuralgia (PHN), a serious complication that can occur after a bout with shingles.
Celldex Therapeutics, Inc. today reported financial results for the third quarter ended September 30, 2010. Celldex reported a net loss of $9.1 million, or $0.28 per share, for the third quarter of 2010 compared to a net loss of $7.2 million, or $0.45 per share, for the third quarter of 2009. For the nine months ended September 30, 2010, Celldex reported a net loss of $25.2 million, or $0.79 per share, compared to a net loss of $23.6 million, or $1.49 per share, for the nine months ended September 30, 2009.
› Verified 2 days ago